📰 Novo Nordisk's Amycretin Trial Shows Promising Weight Loss Results
Early-stage trial results reveal up to 22% weight loss with the subcutaneous version of their new obesity drug, Amycretin.
Novo Nordisk NVO 0.00%↑ has released promising early-stage trial results for its new obesity treatment, Amycretin. Participants using the subcutaneous version of the drug achieved an average weight loss of 22% over 36 weeks. This groundbreaking result marks a significant step forward in combating obesity, a condition affecting millions worldwide.
Amycretin is a novel drug that combines the effects of two hormones: GLP-1, known for regulating appetite, and amylin, which influences hunger and food intake. This dual mechanism aims to provide effective weight management for individuals struggling with obesity. “These results reinforce our belief in Amycretin’s potential as a powerful tool for weight loss,” said Martin Lange, Novo Nordisk’s head of development.
The study involved 125 participants and explored three different dosage levels. Those who adhered to the highest dosage of 20mg experienced the most dramatic weight loss, while even lower doses showed substantial results. Adverse effects were primarily gastrointestinal and mild to moderate in nature, consistent with other treatments in this category.
In addition to the injectable form, Novo Nordisk is also testing an oral version of Amycretin. Preliminary results from earlier trials showed a 13.1% weight reduction after just 12 weeks. These findings underscore the drug’s versatility and potential to cater to diverse patient needs.
Looking ahead, Novo Nordisk plans further clinical trials to validate these findings and expand Amycretin’s accessibility. With obesity rates on the rise globally, the company’s innovative approach could offer hope to millions seeking effective and sustainable weight-loss solutions.
Source: Novo Nordisk Press Release, Reuters
Disclaimer:
The information and opinions provided in this article are for informational and educational purposes only and should not be considered as investment advice or a recommendation to buy, sell, or hold any financial product, security, or asset. The Future Investors does not provide personalized investment advice and is not a licensed financial advisor. Always do your own research before making any investment decisions and consult with a qualified financial professional before making any investment decisions. Please consult the general disclaimer for more details.